

Paul F Siami

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6183632/publications.pdf>

Version: 2024-02-01

21
papers

1,726
citations

586496

16
h-index

759306

22
g-index

22
all docs

22
docs citations

22
times ranked

1215
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-Term Efficacy and Tolerability of Abdominal Once-Yearly Histrelin Acetate Subcutaneous Implants in Patients with Advanced Prostate Cancer. <i>Prostate Cancer</i> , 2014, 2014, 1-5.	0.4	3
2	A Retrospective Study Evaluating the Efficacy and Tolerability of Intra-abdominal, Once-yearly Histrelin Acetate Subcutaneous Implants in Patients. <i>UroToday International Journal</i> , 2012, 05, .	0.1	1
3	Comparison of the response to treatment between Asian and Caucasian men with benign prostatic hyperplasia: Long-term results from the combination of dutasteride and tamsulosin study. <i>International Journal of Urology</i> , 2012, 19, 1031-1035.	0.5	13
4	Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial. <i>BJU International</i> , 2011, 107, 946-954.	1.3	92
5	Once-daily tiroprium chloride 60%mg extended-release provides effective, long-term relief of overactive bladder syndrome symptoms. <i>Neurourology and Urodynamics</i> , 2011, 30, 1214-1219.	0.8	18
6	The Effects of Combination Therapy with Dutasteride and Tamsulosin on Clinical Outcomes in Men with Symptomatic Benign Prostatic Hyperplasia: 4-Year Results from the CombAT Study. <i>European Urology</i> , 2010, 57, 123-131.	0.9	619
7	Randomized, Double-blind, Placebo-controlled Trial of Flexible-dose Fesoterodine in Subjects With Overactive Bladder. <i>Urology</i> , 2010, 75, 62-68.	0.5	86
8	Efficacy and safety of dutasteride, tamsulosin and their combination in a subpopulation of the CombAT study: 2-year results in Asian men with moderate-to-severe BPH. <i>Prostate Cancer and Prostatic Diseases</i> , 2009, 12, 152-159.	2.0	19
9	The Influence of Baseline Parameters on Changes in International Prostate Symptom Score with Dutasteride, Tamsulosin, and Combination Therapy among Men with Symptomatic Benign Prostatic Hyperplasia and an Enlarged Prostate: 2-Year Data from the CombAT Study. <i>European Urology</i> , 2009, 55, 461-471.	0.9	89
10	Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 2-year data from the CombAT trial. <i>BJU International</i> , 2009, 103, 919-926.	1.3	44
11	Diary and Patient-Reported Outcomes in Patients with Severe Overactive Bladder Switching from Tolterodine Extended Release 4%mg/day to Solifenacin Treatment. <i>Clinical Drug Investigation</i> , 2009, 29, 305-316.	1.1	17
12	The effects of dutasteride, tamsulosin, and the combination on storage and voiding in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the Combination of Avodart and Tamsulosin study. <i>Prostate Cancer and Prostatic Diseases</i> , 2009, 12, 369-374.	2.0	40
13	The Effects of Dutasteride, Tamsulosin and Combination Therapy on Lower Urinary Tract Symptoms in Men With Benign Prostatic Hyperplasia and Prostatic Enlargement: 2-Year Results From the CombAT Study. <i>Journal of Urology</i> , 2008, 179, 616-621.	0.2	268
14	Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: Results of a 12-week, multicenter, open-label, flexible-dose study. <i>Clinical Therapeutics</i> , 2008, 30, 1766-1781.	1.1	49
15	Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and prostate enlargement: the CombAT (Combination of Avodart® and Tj ETQq1 1 0.7843148gBT / Overlock 10		
16	Long-term treatment with darifenacin for overactive bladder: results of a 2-year, open-label extension study. <i>BJU International</i> , 2006, 98, 1025-1032.	1.3	56
17	Long-term sustained improvement in symptoms of benign prostatic hyperplasia with the dual 5alpha-reductase inhibitor dutasteride: results of 4-year studies. <i>BJU International</i> , 2005, 96, 572-577.	1.3	65
18	A multicenter, prospective, open-label study of tolterodine extended-release 4 mg for overactive bladder: The speed of onset of therapeutic assessment trial (STAT). <i>Clinical Therapeutics</i> , 2002, 24, 616-628.	1.1	51

#	ARTICLE	IF	CITATIONS
19	Efficacy and Safety of Ciprofloxacin Oral Suspension Versus Trimethoprim-Sulfamethoxazole Oral Suspension for Treatment of Older Women with Acute Urinary Tract Infection. <i>Journal of the American Geriatrics Society</i> , 2001, 49, 1606-1613.	1.3	12
20	Efficacy and safety of fixed-dose and dose-optimization regimens of sublingual apomorphine versus placebo in men with erectile dysfunction. <i>Urology</i> , 2000, 56, 130-135.	0.5	99
21	BCG in management of transitional cell carcinoma invasive to prostate. <i>Urology</i> , 1989, 34, 381-382.	0.5	3